These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 12470422)

  • 1. Octreotide and octreotate derivatives radiolabeled with yttrium: pharmacokinetics in rats.
    Laznicek M; Laznickova A; Mäcke HR; Eisenwiener K; Reubi JC; Wenger S
    Cancer Biother Radiopharm; 2002 Oct; 17(5):527-33. PubMed ID: 12470422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.
    Laznickova A; Laznicek M; Trejtnar F; Maecke HR; Eisenwiener KP; Reubi JC
    Anticancer Res; 2010 Jun; 30(6):2177-84. PubMed ID: 20651367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 111In-DOTA-NOC and 111I-DOTA-TATE distribution in the target and dose-limiting tissues: conflicting results in vitro and in vivo.
    Cihlo J; Melicharová L; Petrik M; Laznickova A; Laznicek M
    Anticancer Res; 2008; 28(4B):2189-95. PubMed ID: 18751394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
    de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
    Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.
    Lewis JS; Laforest R; Lewis MR; Anderson CJ
    Cancer Biother Radiopharm; 2000 Dec; 15(6):593-604. PubMed ID: 11190491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
    Maina T; Nock BA; Cordopatis P; Bernard BF; Breeman WA; van Gameren A; van den Berg R; Reubi JC; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):831-40. PubMed ID: 16568203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.
    Trejtnar F; Novy Z; Petrik M; Laznickova A; Melicharova L; Vankova M; Laznicek M
    Ann Nucl Med; 2008 Dec; 22(10):859-67. PubMed ID: 19142704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor affinity and preclinical biodistribution of radiolabeled somatostatin analogs.
    Laznicek M; Laznickova A; Maecke HR
    Anticancer Res; 2012 Mar; 32(3):761-6. PubMed ID: 22399589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.
    Capello A; Krenning EP; Breeman WA; Bernard BF; Konijnenberg MW; de Jong M
    Cancer Biother Radiopharm; 2003 Oct; 18(5):761-8. PubMed ID: 14629824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
    Velikyan I; Xu H; Nair M; Hall H
    Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
    Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
    Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary PET/CT Imaging with Somatostatin Analogs [
    Satpati D; Shinto A; Kamaleshwaran KK; Sarma HD; Dash A
    Mol Imaging Biol; 2017 Dec; 19(6):878-884. PubMed ID: 28349291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
    J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs.
    Müller C; Forrer F; Bernard BF; Melis M; Konijnenberg M; Krenning EP; de Jong M
    Cancer Biother Radiopharm; 2007 Feb; 22(1):151-9. PubMed ID: 17627424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.
    Breeman WA; Mearadji A; Capello A; Bernard BF; van Eijck CH; Krenning EP; de Jong M
    Int J Cancer; 2003 Apr; 104(3):376-9. PubMed ID: 12569562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging.
    Liu Z; Pourghiasian M; Bénard F; Pan J; Lin KS; Perrin DM
    J Nucl Med; 2014 Sep; 55(9):1499-505. PubMed ID: 24970911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
    Laznickova A; Laznicek M; Trejtnar F; Melicharova L; Suzuki KH; Akizawa H; Arano Y; Yokoyama A
    Eur J Drug Metab Pharmacokinet; 2002; 27(1):37-43. PubMed ID: 11996325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.